AMDA Pocket Guidelines

Dementia Depression Delirium

AMDA GUIDELINES App Bundle brought to you courtesy of AMDA and Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512442

Contents of this Issue

Navigation

Page 26 of 53

27 Galantamine (Razadyne, Razadyne ER) $ Memantine (Namenda, Namenda XR) $$$ Memantine HCl and donepezil HCl (combo) Namzaric $$$$ Mild to moderate Alzheimer's dementia Alzheimer's disease (moderate to severe) Moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily. Twice daily (Razadyne): Start at 4 mg every 12 h, increase to 8 mg every 12 h aer 4 wk; recommended dosage 8 or 12 mg every 12 h Once daily (Razadyne ER): Start with one 8 mg capsule daily (preferably with food) and increase to 16 mg/day aer 4 wk; may increase to 24 mg/day aer another 4 wk Note: Galantamine also available in oral solution (4 mg/mL) IR: Initial: 5 mg daily increased by 5 mg daily to a target of 10 mg twice daily. Titrating no more frequently than once every 7 days. XR: 7 mg once daily increasing by 7 mg daily to a target of 28 mg daily. Titrating no more frequent than once every 7 days. Initial: 7 mg/10 mg, taken once daily in the evening Max: 28 mg/10 mg Defined as those occurring at a frequency of at least 5% and at least twice the placebo rate: Nausea, vomiting, diarrhea and anorexia Diarrhea and dizziness See individual agents. Headache, diarrhea, and dizziness 7–8 60–80 See individual agents Liver Partially hepatic Partially hepatic Administer with food Administer without regard to meals See individual agents 18% 45% See individual agents

Articles in this issue

view archives of AMDA Pocket Guidelines - Dementia Depression Delirium